Oxford Immunotec Global PLC (NASDAQ:OXFD) Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC raised its holdings in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 90.3% in the second quarter, Holdings Channel reports. The fund owned 556,000 shares of the company’s stock after buying an additional 263,900 shares during the period. Renaissance Technologies LLC’s holdings in Oxford Immunotec Global were worth $7,651,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in OXFD. Aperio Group LLC acquired a new stake in Oxford Immunotec Global in the 2nd quarter valued at about $42,000. BNP Paribas Arbitrage SA increased its holdings in shares of Oxford Immunotec Global by 59,988.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 5,408 shares of the company’s stock worth $93,000 after buying an additional 5,399 shares during the last quarter. C M Bidwell & Associates Ltd. acquired a new stake in shares of Oxford Immunotec Global during the 2nd quarter worth approximately $93,000. GSA Capital Partners LLP acquired a new stake in shares of Oxford Immunotec Global during the 2nd quarter worth approximately $173,000. Finally, Campbell & CO Investment Adviser LLC increased its holdings in shares of Oxford Immunotec Global by 15.0% during the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 24,941 shares of the company’s stock worth $343,000 after buying an additional 3,255 shares during the last quarter. Institutional investors own 94.09% of the company’s stock.

In related news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $19.90, for a total value of $59,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Peter Wrighton-Smith sold 10,000 shares of Oxford Immunotec Global stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $13.86, for a total transaction of $138,600.00. Following the completion of the sale, the chief executive officer now owns 424,538 shares of the company’s stock, valued at approximately $5,884,096.68. The disclosure for this sale can be found here. 4.21% of the stock is currently owned by company insiders.



Shares of NASDAQ OXFD traded up $0.28 during midday trading on Wednesday, reaching $17.19. 6,184 shares of the stock were exchanged, compared to its average volume of 111,030. The company has a 50 day simple moving average of $13.82 and a 200 day simple moving average of $14.80. The stock has a market capitalization of $390.39 million, a P/E ratio of 33.75 and a beta of 0.37. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.76 and a current ratio of 13.35. Oxford Immunotec Global PLC has a twelve month low of $11.88 and a twelve month high of $19.19.

Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.07. The business had revenue of $19.60 million during the quarter, compared to the consensus estimate of $19.32 million. Oxford Immunotec Global had a net margin of 208.48% and a return on equity of 14.76%. The business’s revenue was up 17.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.25) EPS. On average, research analysts expect that Oxford Immunotec Global PLC will post -0.17 earnings per share for the current year.

OXFD has been the subject of a number of recent analyst reports. BidaskClub upgraded shares of Oxford Immunotec Global from a “strong sell” rating to a “sell” rating in a report on Friday, September 20th. Zacks Investment Research downgraded shares of Oxford Immunotec Global from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. TheStreet downgraded shares of Oxford Immunotec Global from a “c-” rating to a “d+” rating in a report on Monday, July 15th. Piper Jaffray Companies set a $20.00 price target on shares of Oxford Immunotec Global and gave the stock a “buy” rating in a report on Wednesday, September 18th. Finally, ValuEngine upgraded shares of Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. Oxford Immunotec Global has an average rating of “Hold” and a consensus price target of $19.00.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Recommended Story: Why does the United States have a lingering trade deficit?

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.